Myelodysplastic Syndromes: Introduction

Seminars in Hematology

Volumn 45, Issue 1, 2008, Pages 1-2

  Sloand, Elaine M ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; METHYLTRANSFERASE INHIBITOR;

CHILDHOOD LEUKEMIA; CYTOPENIA; DISEASE COURSE; DRUG EFFICACY; DYSPLASIA; EDITORIAL; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; WORLD HEALTH ORGANIZATION;

AZACITIDINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 37549014945     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.11.008     Document Type: Editorial

References (13)

1. Heaney M.L., and Golde D.W. Myelodysplasia. N Engl J Med 340 (1999) 1649-1660
2. de Witte T., Suciu S., Verhoef G., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98 (2001) 2326-2331
3. de Witte T., Suciu S., Verhoef G., et al. Intensive chemotherapy followed by allogeneic or autologoius stem cell translantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98 (2002) 2326-2331
4. Wong R., Shahjahan M., Wang X., et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant 11 (2005) 108-114
5. Jadersten M., Montgomery S.M., Dybedal I., Porwit-MacDonald A., and Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood (2005)
6. van den B.J., Lubbert M., Verhoef G., and Wijermans P.W. The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 28 (2004) 785-790
7. List A., Kurtin S., Roe D.J., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
8. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 20 (2002) 2429-2440
9. Silverman L.R. DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol 17 (2004) 585-594
10. Hasle H., Wadsworth L.D., Massing B.G., McBride M., and Schultz K.R. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol 106 (1999) 1027-1032
11. Hasle H., Kerndrup G., and Jacobsen B.B. Childhood myelodysplastic syndrome in Denmark: Include and predisposing conditions. Leukemia 9 (1995) 1569-1572
12. Polychronopoulou S., Panagiotou J.P., Kossiva L., et al. Clinical and morphological features of paediatric myelodysplastic syndromes: A review of 34 cases. Acta Paediatr 93 (2004) 1015-1023
13. McKenna R.W. Myelodysplasia and myeloproliferative disorders in children. Am J Clin Pathol 122 suppl (2004) S58-S69